Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOCRYST PHARMACEUTICALS INCBCRX · Entity 315 | Senior Vice President and CFO | February 21, 2020 | February 25, 2020 |
| TENAX THERAPEUTICS, INC.TENX · Entity 979 | Chief Financial Officer | September 11, 2026 | September 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOCRYST PHARMACEUTICALS INC
Report date February 21, 2020 · Filed February 25, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Emp. Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.13 · Expires 2024-12-22 | Direct | 18,000 |
Reported balance
After 2020-02-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-02-21 · Grant · Acquired 18,000 · Balance 18,000 F1: On February 21, 2020, the company received payment for 20,000 doses of RAPIVAB? (peramivir injection) delivered to the U.S. Department of Health and Human Services under the company's procurement contract. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in December 2014, excluding the Chief Executive Officer, has been met. Therefore, 20% of the performance-based stock options vested. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 21, 2020, the company received payment for 20,000 doses of RAPIVAB? (peramivir injection) delivered to the U.S. Department of Health and Human Services under the company's procurement contract. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in December 2014, excluding the Chief Executive Officer, has been met. Therefore, 20% of the performance-based stock options vested.
TENAX THERAPEUTICS, INC.
Report date September 11, 2026 · Filed September 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,675 |
Reported balance
After 2026-09-11 transaction · row 1
1 source rowRow 1 · 2026-09-11 · Purchase · Acquired 5,675 · Balance 15,675 F1: This transaction was executed in multiple trades at prices ranging from $1.90 to $1.95. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.95 · Expires 2036-05-11 | Direct | 450,000 |
Reported balance
Holding disclosure · report date 2026-09-11 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 450,000 F2: The options vest and become exercisable as follows: 25% vest on May 11, 2027, and thereafter, the remainder vest in substantially equal installments on each monthly anniversary of the grant date for a period of 36 months, subject to the Reporting Person's continued employment. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $1.90 to $1.95. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
F2: The options vest and become exercisable as follows: 25% vest on May 11, 2027, and thereafter, the remainder vest in substantially equal installments on each monthly anniversary of the grant date for a period of 36 months, subject to the Reporting Person's continued employment.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
LENSAR, Inc.
Report date May 06, 2026 · Filed May 08, 2026
Section 16 reporting ended · disclosed 2026-05-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 174,609 |
Reported balance
After 2026-05-06 transaction · row 1
1 source rowRow 1 · 2026-05-06 · Tax withholding · Disposed 1,350 · Balance 174,609 F1: Reflects shares of common stock withheld by the Issuer to satisfy tax withholding obligations incident to vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects shares of common stock withheld by the Issuer to satisfy tax withholding obligations incident to vesting of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 04, 2019 Filed Apr 8, 2019 18:30 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 7,500 | $5.51 | $41,325.00 |
DisclosureSEC source: 0001127602-19-014988 · form4.xml · nonDerivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,176 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2019. Read SEC document |
| January 28, 2019 Filed Jan 30, 2019 21:10 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $5.45 | $0.00 |
DisclosureSEC source: 0001127602-19-003053 · form4.xml · derivative · entry 3 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 5,000 shares Expires 2023-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| January 28, 2019 Filed Jan 30, 2019 21:10 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 5,000 | $9.85 | $49,250.00 |
DisclosureSEC source: 0001127602-19-003053 · form4.xml · nonDerivative · entry 2 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,426 F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| January 28, 2019 Filed Jan 30, 2019 21:10 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 5,000 | $5.45 | $27,250.00 |
DisclosureSEC source: 0001127602-19-003053 · form4.xml · nonDerivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| January 01, 2019 Filed Jan 3, 2019 21:30 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Tax withholdingCommon Stock | 785 | $8.07 | $6,334.95 |
DisclosureSEC source: 0001127602-19-000710 · form4.xml · nonDerivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,676 F1 · shares: Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2015. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 21:06 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 235,000 | $0.00 Strike: $7.06 | $0.00 |
DisclosureSEC source: 0001127602-18-037166 · form4.xml · derivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,000 Underlying: Common Stock · 235,000 shares Expires 2028-12-20 F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 21:30 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 3,922 | $9.45 | $37,062.90 |
DisclosureSEC source: 0001127602-18-035386 · form4.xml · nonDerivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,461 Read SEC document |
| November 23, 2018 Filed Nov 26, 2018 21:19 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 3,500 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001127602-18-034301 · form4.xml · derivative · entry 9 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,305 Underlying: Common Stock · 3,500 shares Expires 2021-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| November 23, 2018 Filed Nov 26, 2018 21:19 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 3,500 | $9.66 | $33,810.00 |
DisclosureSEC source: 0001127602-18-034301 · form4.xml · nonDerivative · entry 6 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,383 F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. F4 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $9.65 to $9.69. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| November 23, 2018 Filed Nov 26, 2018 21:19 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 3,500 | $3.78 | $13,230.00 |
DisclosureSEC source: 0001127602-18-034301 · form4.xml · nonDerivative · entry 5 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,883 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| November 21, 2018 Filed Nov 26, 2018 21:19 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001127602-18-034301 · form4.xml · derivative · entry 8 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,805 Underlying: Common Stock · 7,000 shares Expires 2021-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| November 21, 2018 Filed Nov 26, 2018 21:19 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $5.45 | $0.00 |
DisclosureSEC source: 0001127602-18-034301 · form4.xml · derivative · entry 7 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 5,000 shares Expires 2023-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| November 21, 2018 Filed Nov 26, 2018 21:19 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 7,000 | $9.08 | $63,560.00 |
DisclosureSEC source: 0001127602-18-034301 · form4.xml · nonDerivative · entry 4 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,383 F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. F3 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.95 to $9.21. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| November 21, 2018 Filed Nov 26, 2018 21:19 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 7,000 | $3.78 | $26,460.00 |
DisclosureSEC source: 0001127602-18-034301 · form4.xml · nonDerivative · entry 3 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,383 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| November 21, 2018 Filed Nov 26, 2018 21:19 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 5,000 | $9.41 | $47,050.00 |
DisclosureSEC source: 0001127602-18-034301 · form4.xml · nonDerivative · entry 2 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,383 F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $9.40 to $9.42. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| November 21, 2018 Filed Nov 26, 2018 21:19 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 5,000 | $5.45 | $27,250.00 |
DisclosureSEC source: 0001127602-18-034301 · form4.xml · nonDerivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,383 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 21:48 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001127602-18-034192 · form4.xml · derivative · entry 9 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,071 Underlying: Common Stock · 6,500 shares Expires 2026-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 21:48 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 4,623 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001127602-18-034192 · form4.xml · derivative · entry 8 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,805 Underlying: Common Stock · 4,623 shares Expires 2021-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 21:48 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 6,500 | $8.75 | $56,875.00 |
DisclosureSEC source: 0001127602-18-034192 · form4.xml · nonDerivative · entry 6 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,383 F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. F3 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.75 to $8.76. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 21:48 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 6,500 | $3.22 | $20,930.00 |
DisclosureSEC source: 0001127602-18-034192 · form4.xml · nonDerivative · entry 5 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,883 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 21:48 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 4,623 | $8.57 | $39,619.11 |
DisclosureSEC source: 0001127602-18-034192 · form4.xml · nonDerivative · entry 4 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,383 F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.30 to $8.66. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 21:48 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 4,623 | $3.78 | $17,474.94 |
DisclosureSEC source: 0001127602-18-034192 · form4.xml · nonDerivative · entry 3 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,006 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| November 19, 2018 Filed Nov 21, 2018 21:48 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 75 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001127602-18-034192 · form4.xml · derivative · entry 7 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,428 Underlying: Common Stock · 75 shares Expires 2021-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| November 19, 2018 Filed Nov 21, 2018 21:48 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 75 | $8.30 | $622.50 |
DisclosureSEC source: 0001127602-18-034192 · form4.xml · nonDerivative · entry 2 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,383 F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| November 19, 2018 Filed Nov 21, 2018 21:48 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 75 | $3.78 | $283.50 |
DisclosureSEC source: 0001127602-18-034192 · form4.xml · nonDerivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,458 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| November 08, 2018 Filed Nov 9, 2018 21:14 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 2,302 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001127602-18-032645 · form4.xml · derivative · entry 9 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,503 Underlying: Common Stock · 2,302 shares Expires 2021-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| November 08, 2018 Filed Nov 9, 2018 21:14 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 11,113 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001127602-18-032645 · form4.xml · derivative · entry 8 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,571 Underlying: Common Stock · 11,113 shares Expires 2026-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| November 08, 2018 Filed Nov 9, 2018 21:14 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 2,302 | $8.30 | $19,106.60 |
DisclosureSEC source: 0001127602-18-032645 · form4.xml · nonDerivative · entry 6 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,383 F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| November 08, 2018 Filed Nov 9, 2018 21:14 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 2,302 | $3.78 | $8,701.56 |
DisclosureSEC source: 0001127602-18-032645 · form4.xml · nonDerivative · entry 5 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,685 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| November 08, 2018 Filed Nov 9, 2018 21:14 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 11,113 | $8.09 | $89,904.17 |
DisclosureSEC source: 0001127602-18-032645 · form4.xml · nonDerivative · entry 4 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,383 F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.00 to $8.15. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| November 08, 2018 Filed Nov 9, 2018 21:14 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 11,113 | $3.22 | $35,783.86 |
DisclosureSEC source: 0001127602-18-032645 · form4.xml · nonDerivative · entry 3 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,496 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| November 07, 2018 Filed Nov 9, 2018 21:14 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 672 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001127602-18-032645 · form4.xml · derivative · entry 7 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,684 Underlying: Common Stock · 672 shares Expires 2026-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| November 07, 2018 Filed Nov 9, 2018 21:14 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 672 | $8.00 | $5,376.00 |
DisclosureSEC source: 0001127602-18-032645 · form4.xml · nonDerivative · entry 2 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,383 F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| November 07, 2018 Filed Nov 9, 2018 21:14 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 672 | $3.22 | $2,163.84 |
DisclosureSEC source: 0001127602-18-032645 · form4.xml · nonDerivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,055 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| November 05, 2018 Filed Nov 7, 2018 21:03 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 215 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001127602-18-032411 · form4.xml · derivative · entry 3 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,356 Underlying: Common Stock · 215 shares Expires 2026-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| November 05, 2018 Filed Nov 7, 2018 21:03 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 215 | $8.00 | $1,720.00 |
DisclosureSEC source: 0001127602-18-032411 · form4.xml · nonDerivative · entry 2 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,383 F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| November 05, 2018 Filed Nov 7, 2018 21:03 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 215 | $3.22 | $692.30 |
DisclosureSEC source: 0001127602-18-032411 · form4.xml · nonDerivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,598 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 21:04 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 3,500 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001127602-18-032273 · form4.xml · derivative · entry 6 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,805 Underlying: Common Stock · 3,500 shares Expires 2021-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 21:04 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 7,356 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001127602-18-032273 · form4.xml · derivative · entry 5 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,571 Underlying: Common Stock · 7,356 shares Expires 2026-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 21:04 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 3,500 | $7.96 | $27,860.00 |
DisclosureSEC source: 0001127602-18-032273 · form4.xml · nonDerivative · entry 4 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,383 F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. F3 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.95 to $7.96. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 21:04 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 3,500 | $3.78 | $13,230.00 |
DisclosureSEC source: 0001127602-18-032273 · form4.xml · nonDerivative · entry 3 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,883 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 21:04 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 7,356 | $7.78 | $57,229.68 |
DisclosureSEC source: 0001127602-18-032273 · form4.xml · nonDerivative · entry 2 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,383 F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.74 to $8.00. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 21:04 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 7,356 | $3.22 | $23,686.32 |
DisclosureSEC source: 0001127602-18-032273 · form4.xml · nonDerivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,739 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| October 19, 2018 Filed Oct 23, 2018 17:34 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 3,150 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001127602-18-030771 · form4.xml · derivative · entry 3 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,305 Underlying: Common Stock · 3,150 shares Expires 2021-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| October 19, 2018 Filed Oct 23, 2018 17:34 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 3,150 | $7.45 | $23,467.50 |
DisclosureSEC source: 0001127602-18-030771 · form4.xml · nonDerivative · entry 2 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,383 F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.45 to $7.46. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| October 19, 2018 Filed Oct 23, 2018 17:34 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 3,150 | $3.78 | $11,907.00 |
DisclosureSEC source: 0001127602-18-030771 · form4.xml · nonDerivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,533 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| October 03, 2018 Filed Oct 4, 2018 17:09 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 100 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001127602-18-029520 · form4.xml · derivative · entry 12 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,455 Underlying: Common Stock · 100 shares Expires 2021-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| October 03, 2018 Filed Oct 4, 2018 17:09 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 972 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001127602-18-029520 · form4.xml · derivative · entry 11 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,927 Underlying: Common Stock · 972 shares Expires 2026-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| October 03, 2018 Filed Oct 4, 2018 17:09 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 100 | $7.45 | $745.00 |
DisclosureSEC source: 0001127602-18-029520 · form4.xml · nonDerivative · entry 8 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,383 F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| October 03, 2018 Filed Oct 4, 2018 17:09 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 100 | $3.78 | $378.00 |
DisclosureSEC source: 0001127602-18-029520 · form4.xml · nonDerivative · entry 7 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.